Profile
International Journal of Clinical Pharmacology & Pharmacotherapy Volume 3 (2018), Article ID 3:IJCPP-137, 5 pages
https://doi.org/10.15344/2456-3501/2018/137
Original Article
The Relevance of High Pulse Pressure and Renal Function in Patients with Chronic Kidney Disease: Analysis for each Stage of Chronic Kidney Disease

Eiji Kose1*, Taesong An2 and Akihiko Kikkawa2

1Department of Pharmacotherapy, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan
2Department of Pharmacy, Yokosuka Kyousai Hospital, 1-16 Yonegahamadohri, Yokosuka-shi, Kanagawa 238-8588, Japan
Dr. Eiji Kose, Department of Pharmacotherapy, School of Pharmacy, Nihon University, 7-7-1 Narashinodai, Funabashi-shi, Chiba 274-8555, Japan, Tel: +81-47-465-2096, Fax: +81-47-465-2096; E-mail: kose.eiji@nihon-u.ac.jp
29 March 2018; 08 May 2018; 10 May 2018
Kose E, An T, Kikkawa A (2018) The Relevance of High Pulse Pressure and Renal Function in Patients with Chronic Kidney Disease: Analysis for each Stage of Chronic Kidney Disease. Int J Clin Pharmacol Pharmacother 3: 137. doi: https://doi.org/10.15344/2456-3501/2018/137

Abstract

Background: In our previous study, we showed that high pulse pressure (PP) is associated with decreased renal function in chronic kidney disease (CKD) patients. In recent years, there were a few reports that CKD stage classification focused on glomerular filtration rate, which is associated with the occurrence of cardiovascular disease, deterioration of renal prognosis, and life prognosis. We aim to examine the relationship between increased PP and renal function according to each CKD stage classification.
Methods: The present study includes 104 participants with CKD (stage G3a-G5) who visited the Nephrology Medicine Department of Yokosuka Kyousai Hospital between September 2006 and October 2011. The participants were categorized on the basis of PP: ≥65 mmHg was the High PP group, and <65 mmhg was the low pp group. we compared two groups with regard to patient background characteristics, laboratory data from baseline, and12 months later.
Results: Renal function deteriorated between the baseline and 12 months later at CKD stage G4-G5 in both, the Low and High PP groups; however, there were no significant differences at CKD stage G3a-G3b in both the groups. Changes in renal function at CKD stage G4-G5 in the Low PP group and High PP group were compared for one year from the baseline. ΔBUN, ΔSCr, and ΔeGFR were worsened in the High PP group compared to the Low PP group.
Conclusions: Decrease in renal function may be reflected in the advanced CKD stage in which PP has increased.